Aclerastide

• CAT Number: I001117
• CAS Number: 227803-63-6
• Molecular Formula: C42H64N12O11
• Molecular Weight: 913.03
• Purity: ≥95%
• Synonyms: (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
• InChI: InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1
• InChIKey: RUBMHAHMIJSMHA-LBWFYSSPSA-N
• SMILES: CCCCC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)CC)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N

Aclerastide (Cat No.: I001117) is a synthetic peptide analog of angiotensin II, developed to enhance wound healing, particularly in chronic diabetic foot ulcers. It functions by stimulating angiogenesis and promoting tissue repair through activation of the angiotensin II type 1 receptor (AT1R), leading to increased blood flow and cellular regeneration. Although it showed promise in early clinical trials, later studies did not demonstrate sufficient efficacy for approval. Nonetheless, aclerastide remains a valuable compound in research on peptide therapeutics and wound healing mechanisms.

Reference

[1]. Kathleen E Rodgers, et al. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar;111(3):1195-206.
[Content Brief]

[2]. Trung T Nguyen, et al. Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers. Eur J Pharmacol. 2018 Sep 5;834:77-83.
[Content Brief]